Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07697612

Durian Consumption in Adults With Type 2 Diabetes Mellitus

This single-arm clinical trial investigates the effects of daily durian consumption on the gut microbiome, host metabolome, and glucose metrics in adults with type 2 diabetes mellitus (T2DM). Forty adults with T2DM will undergo a pre-durian phase, a durian consumption phase, and a post-durian phase, each lasting 10 to 14 days. Participants will attend five visits at Singapore General Hospital for clinical assessments, continuous glucose monitoring, fasting blood collection, stool sample collection, and dietary and stool record submission. The study aims to determine whether durian consumption alters microbiome and metabolomic profiles and whether it affects glycemic measures in adults with T2DM.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

21 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Singapore General Hospital

Singapore

Location contact

Hong Chang Tan, MD PhD

CONTACT

[email protected]

6222 3322

Hong Chang Tan, MD PhD

PRINCIPAL_INVESTIGATOR

About this study

Durian is a widely consumed tropical fruit with high fiber content and multiple bioactive compounds, including phenolics, flavonoids, carotenoids, and volatile sulfur compounds. Although animal and limited human studies suggest possible metabolic effects, the impact of durian consumption on gut microbiota and host metabolomic profiles in adults with type 2 diabetes mellitus remains unclear. This single-arm interventional study will enroll 40 adults with T2DM at Singapore General Hospital. Participants will complete five study visits over approximately 1.5 to 3 months. After screening, eligible participants will enter a pre-durian phase, a durian phase, and a post-durian phase, each lasting 10 to 14 days. During the durian phase, participants will consume 100 g of durian on Day 1 and 200 g daily from Day 2 onward for 10 to 14 days. Continuous glucose monitoring will be performed across study phases. Blood samples will be analyzed for clinical laboratory parameters, inflammatory markers, metabolomics, and genetic/epigenetic analyses. Stool samples will undergo metagenomic sequencing and metabolomic analysis. The study hypothesis is that durian consumption will result in significant changes in the gut microbiome and metabolome of individuals with T2DM without adversely affecting gluometric measures.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 21 to 70 years.
  • Diagnosis of type 2 diabetes mellitus.
  • Agrees to consume durian for 2 weeks.
  • Body mass index 25 to 40 kg/m².

Exclusion criteria

  • Known or suspected intolerance or allergy to durian.
  • Known skin reaction to adhesives used in a continuous glucose sensor.
  • Uncontrolled diabetes (HbA1c greater than 8.5%).
  • Severe hypertriglyceridemia (triglycerides greater than 4.5 mmol/L).
  • Smoking.
  • Previous gastrointestinal surgeries, including cholecystectomy, gastrectomy, bariatric surgery, or colectomy.
  • Inflammatory bowel disease.
  • Glomerular filtration rate less than 30 mL/min.
  • ALT greater than 3 times upper limit of normal.
  • AST greater than 3 times upper limit of normal.
  • Liver cirrhosis.
  • Significant alcohol consumption, defined as more than 20 g/day for women and more than 30 g/day for men.
  • Pregnant, breastfeeding, or intending to conceive during the study.
  • Current hemorrhoids or piles causing rectal bleeding during stool passage.
  • Systemic steroid use.
  • Insulin use.
  • Weight loss medications, including GLP-1 receptor agonists, orlistat, or phentermine.
  • Antibiotic, prebiotic, probiotic, vitamin C, or traditional Chinese medicine use in the last 1 month.
  • Uncontrolled thyroid disease.
  • Any factor likely to limit adherence to study protocol, including dementia, substance abuse, poor appointment adherence, or family concerns regarding participation

Treatment and study plan

Durian pulp

Dietary Supplement

Fresh durian pulp supplied by the study team. Participants consume 100 g on Day 1, then 200 g daily from Day 2 onward during the durian phase for 10 to 14 days. Participants record the timing and amount consumed each day.

Primary outcomes

  1. Change in gut microbiome composition following durian consumption

    Time frame: Baseline to end of durian phase, approximately 10 to 14 days; and through post-durian phase, approximately 20 to 28 days from baseline phase start

    Gut microbiome composition will be assessed from stool samples using comprehensive metagenomic sequencing, comparing pre-durian, durian, and post-durian phases.

  2. Change in plasma metabolomic profile following durian consumption

    Time frame: Baseline to end of durian phase, approximately 10 to 14 days; and through post-durian phase, approximately 20 to 28 days from baseline phase start

    Plasma metabolomic changes will be assessed using mass spectrometry-based multi-omics profiling across study phases.

  3. Change in glucose metrics during and after durian consumption

    Time frame: During pre-durian, durian, and post-durian phases, each approximately 10 to 14 days

    Continuous glucose monitoring data will be used to evaluate interstitial glucose patterns and gluometric parameters across study phases.

Secondary outcomes

  1. Change in fasting plasma glucose

    Time frame: Baseline to end of durian phase, approximately 10 to 14 days; and through post-durian phase, approximately 20 to 28 days from baseline phase start

    Fasting glucose measured from blood samples across study visits.

  2. Change in fasting insulin

    Time frame: Baseline to end of durian phase, approximately 10 to 14 days; and through post-durian phase, approximately 20 to 28 days from baseline phase start

    Fasting insulin measured from blood samples across study visits.

  3. Change in lipid profile

    Time frame: Baseline to end of durian phase, approximately 10 to 14 days; and through post-durian phase, approximately 20 to 28 days from baseline phase start

    Lipid panel measured from fasting blood samples across study visits.

Study contacts

Contact information is provided by the study sponsor or research team.

Hong Chang Tan, MD, PhD

CONTACT

[email protected]

+65-6222 3322

Sponsors and collaborators

Lead sponsor

Singapore General Hospital

Other

Registry information

Official study title

Durian Consumption on Human Microbiome and Metabolome in Adults With Type 2 Diabetes Mellitus (DURIOME-T2D)

Acronym: DURIOME-T2D

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Jul 13, 2026
Registry last updated
Jul 13, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.